David Smoley, CIO at AstraZeneca since April, 2013, says, “Finally, we are really starting to tap into the startup community. We are working with many companies that didn’t exist five years ago, who typically have developed their products with only cloud, mobile and usability in mind.”
He notes the incredible value the company has gained from working with technology startups. “With the advances in cloud computing, this has enabled our business to tap into new approaches, such as deep learning for drug repositioning, machine learning for patient stratification, image recognition for digital pathology, advanced data compression for genomics, lightning-quick databases for mobile apps, smart wrangling tools for clinical data, new social channels for teams, influencer identification across social media and new IoT sensors alerting us to anomalies in our lab equipment before they break.”
But there is still room for further partnerships with startup companies and innovators. "There are many other areas and learning from approaches that our R&D colleagues have explored in the past few years,” says Smoley, “we are starting to explore opportunities to engage both inside and outside AstraZeneca using open innovation challenges."